Teva Pharmaceutical Industries Limited (NYSE:TEVA) has been assigned a $20.00 price target by research analysts at Wells Fargo & Company in a note issued to investors on Wednesday. The firm currently has a “hold” rating on the stock. Wells Fargo & Company’s price target would suggest a potential upside of 27.55% from the stock’s current price.

Other equities analysts also recently issued research reports about the stock. Vetr downgraded shares of Teva Pharmaceutical Industries Limited from a “hold” rating to a “sell” rating and set a $31.05 target price for the company. in a research note on Thursday, June 22nd. Cantor Fitzgerald set a $31.00 target price on shares of Teva Pharmaceutical Industries Limited and gave the stock a “hold” rating in a research note on Thursday, June 22nd. BidaskClub lowered shares of Teva Pharmaceutical Industries Limited from a “sell” rating to a “strong sell” rating in a research report on Wednesday, August 16th. Morgan Stanley set a $15.00 price objective on shares of Teva Pharmaceutical Industries Limited and gave the company a “sell” rating in a research report on Thursday. Finally, Citigroup Inc. lowered shares of Teva Pharmaceutical Industries Limited from a “buy” rating to a “neutral” rating and cut their price objective for the company from $32.00 to $19.00 in a research report on Wednesday, August 16th. Five research analysts have rated the stock with a sell rating, eighteen have assigned a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. The stock has an average rating of “Hold” and an average target price of $28.72.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) traded down 2.49% during mid-day trading on Wednesday, reaching $15.68. 37,585,420 shares of the company’s stock were exchanged. The company has a 50-day moving average of $16.94 and a 200-day moving average of $26.89. The stock’s market cap is $15.93 billion. Teva Pharmaceutical Industries Limited has a 52-week low of $15.22 and a 52-week high of $45.85. Teva Pharmaceutical Industries Limited also was the recipient of unusually large options trading activity on Wednesday. Traders acquired 29,656 put options on the stock. This represents an increase of approximately 231% compared to the typical volume of 8,957 put options.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last posted its earnings results on Thursday, August 3rd. The company reported $0.99 earnings per share for the quarter, missing the consensus estimate of $1.06 by ($0.07). The business had revenue of $5.69 billion during the quarter, compared to analysts’ expectations of $5.72 billion. Teva Pharmaceutical Industries Limited had a positive return on equity of 15.96% and a negative net margin of 25.18%. Teva Pharmaceutical Industries Limited’s revenue for the quarter was up 12.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.25 EPS. Equities research analysts anticipate that Teva Pharmaceutical Industries Limited will post $4.28 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another domain, it was stolen and republished in violation of international trademark and copyright laws. The original version of this piece of content can be accessed at https://www.watchlistnews.com/teva-pharmaceutical-industries-limited-teva-given-a-20-00-price-target-at-wells-fargo-company/1611184.html.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Perpetual Ltd bought a new stake in shares of Teva Pharmaceutical Industries Limited in the 2nd quarter worth approximately $2,865,000. WFG Advisors LP lifted its holdings in shares of Teva Pharmaceutical Industries Limited by 2,650.1% in the 2nd quarter. WFG Advisors LP now owns 29,784 shares of the company’s stock worth $989,000 after acquiring an additional 28,701 shares during the last quarter. Oak Associates Ltd. OH lifted its holdings in shares of Teva Pharmaceutical Industries Limited by 0.6% in the 2nd quarter. Oak Associates Ltd. OH now owns 379,924 shares of the company’s stock worth $12,621,000 after acquiring an additional 2,114 shares during the last quarter. Cetera Investment Advisers bought a new stake in shares of Teva Pharmaceutical Industries Limited in the 2nd quarter worth approximately $373,000. Finally, Sterneck Capital Management LLC lifted its holdings in shares of Teva Pharmaceutical Industries Limited by 5.4% in the 2nd quarter. Sterneck Capital Management LLC now owns 131,907 shares of the company’s stock worth $4,382,000 after acquiring an additional 6,702 shares during the last quarter. Hedge funds and other institutional investors own 56.77% of the company’s stock.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with Analyst Ratings Network's FREE daily email newsletter.